WELLESLEY, Mass., Feb. 1 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced today that David Deems has been appointed company president with full executive responsibility for strategic, commercial, and operational development, effective immediately. Michael L. Cohen, who has served as Xceed’s president and CEO since January of 2005, will assume the role of non- executive chairman of the company’s board of directors. Deems, a diagnostics industry executive with more than 20 years experience, was Xceed’s vice president, commercial and business development before his promotion.
“On behalf of the board of directors, we are excited about David Deems moving into this role, and about the noteworthy track record he brings in molecular diagnostic product development, commercialization, and operations,” said Cohen. “David has outstanding experience and credentials in both start-up and mature companies. Since joining Xceed in early 2006, he has been a critical driver of Xceed’s very positive product and business trajectory. We have established a strong foundation for Xceed and are successfully making the transition from a development-stage company to one focused on concrete products and solutions for multiplexed gene expression tests for in vitro diagnostics. This is an ideal time to have David take over the day-to-day leadership of the company.”
In commenting on his new role, Deems said, “Xceed is delivering a powerful system to enable multiplexed molecular diagnostics to migrate into routine clinical practice as in vitro diagnostics. I am excited to have the opportunity to lead Xceed as we work to enable simpler, faster, and more- affordable deployment of multiplexed tests designed to improve patient care, and enhance health outcomes.”
Prior to joining Xceed, Deems was vice president, development and operations at Predicant Biosciences and vice president, product development at Exact Sciences. Earlier in his career, he served as CEO of Union Biometrica, a functional genomics tool company and held a number of executive positions at BD Biosciences.
About Xceed Molecular
Xceed’s vision is to advance molecular diagnostics and improve health outcomes by providing a cost-effective, automated system and services that facilitate the rapid translation of novel multiplexed genomic tests from research into routine clinical use. Our products comprise the Ziplex(TM) System for automated gene-expression analysis (available in the US and Canada for research use only), custom array services, and pre-configured arrays. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed’s R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit www.Xceedmolecular.com.
Xceed Molecular
CONTACT: Caroline Grossman for Xceed Molecular, +1-781-771-5579, orcaroline.grossman@gmail.com; or David Deems of Xceed Molecular,+1-617-899-5597, or ddeems@xceedmolecular.com
Web site: http://www.xceedmolecular.com/
